ImmunotherapiesCongress.comAugust 13-15, 2013 • Hilton Boston Back Bay Hotel • Boston, MA Preliminary AgendaRegister by May 17 and Save up to $300!Organized by:Cambridge Healthtech InstituteInauguralImmunomodulatoryAntibodies for CancerAugust 14-15InauguralEmerging CancerImmunotherapies and VaccinesAugust 13-14Sessions Include:• Cancer Biology and Biomarkers• Emerging CancerImmunotherapies & Vaccines• Clinical Development ofImmunomodulatory Antibodies• Bispecific ImmunomodulatoryAntibodiesKeynote Presentation:The Promise ofT-Cell EngineeringMichel Sadelain, M.D., Ph.D., Director,Center for Cell Engineering & Gene Transferand Gene Expression Laboratory, MemorialSloan-Kettering Cancer CenterImmune Monitoring onPre-surgical Clinical Trials witha Novel Checkpoint BlockadeAgent, Anti-CTLA-4Padmanee Sharma, M.D., AssociateProfessor, Genitourinary MedicalOncology,University of Texas MD AndersonCancer CenterPre-ConferenceShort Course:ImmunotherapyStrategies for MelanomaImmunoTheCongressherapiesImmune System Modulationfor Novel Cancer TreatmentsImmunotherapiesCongress.comCo-Located EventEighth AnnualNovel Vaccines: Innovations & AdjuvantsTo Advance the Science of Vaccines
2ImmunotherapiesCongress.comPre-Conference Short Course * Monday, August 12 • 2:00-5:00Immunotherapy Strategies for MelanomaAs understandings of cancer biology, human genetics and immunology evolve, new strategies for treatment of melanomas with a combination of targeted therapeuticsand immunotherapies are progressing at a rapid pace. This short course will survey the most promising emerging targets for cancer therapeutics and explore how thesewill integrate with cancer vaccines and other immunotherapies for maximum clinical effect.Instructors TBATopics to be discussed:• New advances in knowledge of melanoma biology• New targets (PD-1, PRL-1, CTLA-4, OX40, CD40, GITR, 4-1BB)• Combining targeted agents and immunotherapies• Identification of immunotherapy biomarkers to improve therapeutic efficacy*Separate registration requiredConference Hotel:Hilton Boston Back Bay Hotel40 Dalton StreetBoston, MA 02115Phone: 617-236-1100Discounted Room Rate: $195 s/dDiscounted Room Rate Cut-off Date: July 15, 2013Please visit our conference website to make yourreservations online or call the hotel directly toreserve your sleeping accommodations. Identifyyourself as a Cambridge Healthtech Instituteconference attendee to receive the reducedroom rate. Reservations made after the cut-offdate or after the group room block has beenfilled (whichever comes first) will be accepted ona space-and-rate-availability basis. Rooms arelimited, so please book early.HOTEL & TRAVEL INFORMATIONFlight Discounts:To receive a 5% or greater discount on all American Airline flights please use one of the followingmethods:• Call 1-800-433-1790 use Conference code (8283BJ)• Go online www.aa.com enter Conference code (8283BJ) in promotiondiscount box• Contact Rona Meizler, Great International Travel 1-617-559-3735Car Rental Discounts:Special discount rentals have been established with Hertz for this conference. Please use one of thefollowing methods:• Call HERTZ, 800-654-3131 use our Hertz Convention Number (CV): 04KL0002• Go online www.hertz.com use our Hertz Convention Number (CV): 04KL0002Sponsoring Pubs
3 ImmunotherapiesCongress.comKeynote Presentation:The Promise of T-Cell EngineeringMichel Sadelain, M.D., Ph.D., Director, Center for Cell Engineering& Gene Transfer and Gene Expression Laboratory, Memorial Sloan-Kettering Cancer CenterCancer Biology and BiomarkersAdvances in Biomarker Validation and Trial Design forAntitumor ImmunotherapySusan R. Slovin, M.D., Ph.D., Genitourinary Oncology Service, SidneyKimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer CenterEmerging Cancer ImmunotherapiesIdentifying New Cancer Immunotherapy Targets for T CellsRobert Holt, Ph.D., Head, Sequencing, Michael Smith Genome SciencesCenter, BC Cancer Agency, CanadaAn Antibody Fusion Protein for Cancer ImmunotherapyMimicking IL-15 Trans-Presentation at the Tumor SiteDafne Müller, Ph.D., Researcher, Institute of Cell Biology andImmunology, University of Stuttgart, GermanyTIM (T Cell Immunoglobulin and Mucin)-3 as a Potential Targetfor Cancer ImmunotherapyAna Carrizosa Anderson, Ph.D., Assistant Professor, Harvard MedicalSchoolAllovectin: In vivo Studies and Potential Synergy with OtherAdvanced Melanoma ImmunotherapeuticsJohn Doukas, Ph.D., Senior Director, Preclinical Safety and Efficacy,Vical, Inc.Clinical Update of IL2 Adjunctive Cotherapy for Suppression ofSolid Tumors with Designer T CellsRichard P. Junghans, M.D., Professor, Department of Medicine, BostonUniversity; School of Medicine, Roger Williams Medical CenterEmerging Cancer VaccinesRetrospective Biomarker Studies for ProvengeJames Trager, Ph.D., Vice President, Research, DendreonPartnering Therapeutic Vaccines with Large PharmaKevin Heller, Global Lead, Oncology; Search, Evaluation and Diligence,Bristol-Myers SquibbClinical Results of JX594: Oncolytic Tumor Viruses as aStrategy for Cancer VaccinesAnne Moon, Ph.D., Vice President, Product Development, JennerexClinical Update on PROSTVAC, a Therapeutic Vaccine Candidatefor Advanced Prostate CancerAlain Delcayre, Ph.D., Vice President, R&D, BN ImmunotherapeuticsInauguralEmerging Cancer Immunotherapies and VaccinesNext-Generation Targets and StrategiesAugust 13-14Using lessons learned from early cancer vaccines and immunotherapeutics, a new wave of programs are underway that promise improved efficacyand safety over a wider range of cancers. Emerging Cancer Immunotherapies and Vaccines will examine new targets and strategies in this space,along with important studies in preclinical development associated with developing these programs into successful drug products. Speakers will offerapproaches to resolve the most challenging steps in the transition of these programs from research into clinical development.
4ImmunotherapiesCongress.comThe recent approval of BMS’s Yervoy (ipilumumab) and a succession of related programs advancing through clinical trials has generated increasedinterest in the development of antibody-based immunomodulators for cancer. Immunomodulatory Therapeutic Antibodies for Cancer will provideupdates of clinical stage programs, and examine how these novel therapeutics influence trial design and the selection of clinical endpoints. Strategiesfor immune modulation that are most appropriate for targeting with antibodies will be considered, along with where combination regimens and newtherapeutic formats can be effectively applied.InauguralImmunomodulatory Antibodies for CancerClinical Progress and Challenges in Drug Product DevelopmentAugust 14-15Keynote Presentation:Immune Monitoring on Pre-surgical Clinical Trials with a NovelCheckpoint Blockade Agent, Anti-CTLA-4Padmanee Sharma, M.D., Associate Professor, Genitourinary MedicalOncology, University of Texas MD Anderson Cancer CenterImmune Checkpoint BlockadesClinical Update of MK-3475: A Humanized IgG4 Anti-PD-1Monoclonal Antibody for Progressive, Locally Advanced, orMetastatic Carcinoma, Melanoma, or NSCLCOmid Hamid, M.D., Director, Melanoma Center, Angeles Clinic andResearch InstituteAnti-PD-1 Antibody Therapy for B-Cell LymphomaSattva S. Neelapu, M.D., Associate Professor, Department ofLymphoma and Myeloma, Division of Cancer Medicine, The Universityof Texas MD Anderson Cancer CenterAMP-224, A Fusion Protein with Potential to Modulate the PD-1PathwaySolomon Langermann, Ph.D., CSO, AmplimmuneEmerging TargetsCytokine Fusions for Cancer ImmunotherapyCatherine Hutchinson, Ph.D., Research Scientist, Philochem,SwitzerlandMechanism of Action and Progress Update for MGA271Targeting B7-H3 for Solid TumorsPaul Moore, Ph.D., Vice President, Cell Biology & Immunology,MacrogenicsCDX-1127: An Agonist Anti-CD27 Monoclonal Antibody (mAb)that Activates CD27 Expressing T Cells in the Context of T CellReceptor StimulationLawrence J. Thomas, Ph.D., DABT, CMAR, Senior Director, PreclinicalResearch and Development, Celldex Therapeutics, Inc.ARGX-110: A Potently Neutralizing, Humanized MonoclonalAntibody to CD70 with Enhanced ADCC PropertiesAlain Thibault, M.D., CMO arGEN-X BV, The NetherlandsTargeting CD47-SIRPa Interactions for Potentiating AntibodyTherapy Against Cancer Timo van den Berg, Ph.D., Head, Blood Cell Research, Sanquin, TheNetherlandsClinical Development of ImmunomodulatoryAntibodiesClinical Trials Design for Cancer ImmunotherapeuticsHarriet Kluger M.D., Associate Professor of Medicine (MedicalOncology); Associate Director, Hematology/Oncology FellowshipProgram, Yale Cancer CenterCharacteristics and Management of Immune-Related AdverseEffects Associated with Ipilimumab, a New Immunotherapy forMetastatic MelanomaStephanie Andrews, Oncology Nurse Practitioner, Moffitt Cancer CenterBispecific Immunomodulatory AntibodiesSafety Challenges to Development of Immune SystemActivating AntibodiesRakesh Dixit, Ph.D., DABT, Vice President, Research & Development,Global Head, Biologics Safety Assessment, Pathology & LAR,MedimmuneMCLA-117: A Biclonics – ENGAGE Bispecific IgG Product LeadTargeting CLEC12A and CD3 in AMLLex Bakker, Ph.D., Chief Development Officer, Merus, The NetherlandsBispecific Antibody Targeting CD47 Aiming at IncreasingPhagocytosis of Cancer CellsKrzysztof Masternak, Ph.D., Head, Biology, Novimmune SA, Switzerland
5 ImmunotherapiesCongress.comCHI offers comprehensive sponsorship packages which include presentationopportunities, exhibit space and branding, as well as the use of the pre andpost-show delegate lists. Customizable sponsorship packages allow you toachieve your objectives before, during, and long after the event. Signing onearly will allow you to maximize exposure to hard-to-reach decision makers!Agenda PresentationsShowcase your solutions to a guaranteed,highly-targeted audience.Packageincludes a 15 or 30-minute podium presentation within the scientific agenda,exhibitspace,on-site branding,and access to cooperative marketing efforts by CHI.Breakfast & Luncheon PresentationsOpportunity includes a 30-minute podium presentation. Boxed lunches aredelivered into the main session room, which guarantees audience attendanceand participation. A limited number of presentations are available forsponsorship and they will sell out quickly. Sign on early to secure your talk!Invitation-Only VIP Dinner/Hospitality SuiteSponsors will select their top prospects from the conference pre-registrationlist for an evening of networking at the hotel or at a choice local venue. CHIwill extend invitations and deliver prospects. Evening will be customizedaccording to sponsor’s objectives:• Purely social• Focus group• Reception style• Plated dinner with specific conversation focusExhibitExhibitors will enjoy facilitated networking opportunities with high-levelconference delegates. Speak face-to-face with prospective clients andshowcase your latest product, service, or solution.*Inquire about additional branding opportunities!Looking for additional ways to driveleads to your sales team?CHI can help!We offer clients numerous options for custom lead generation programs toaddress their marketing and sales needs, including:Custom Lead Generation Programs:• Targeted campaign promotion to unparalleled database of800,000+ individuals in the life sciences• Experienced marketing team promotes campaign, increasingawareness and leadsLive Webinars:• Assistance in procuring speakers• Experienced moderators• Dedicated operations team to coordinate all effortsWhite Papers:• Industry recognized authors, with vast editorial experience, availableto help write your white paperCHI also offers market surveys, podcasts, and more!To customize your participation at this event, please contact:Suzanne Carroll – Senior Business Development Manager781-972-5452 | firstname.lastname@example.orgSponsorship, Exhibit, and Lead Generation OpportunitiesCo-Located EventAugust 13-15, 2013 • Hilton Boston Back Bay Hotel • Boston, MAEighth AnnualNovel Vaccines:Innovations & AdjuvantsTo Advance the Science of Vaccines
Additional registration detailsEach registration includes all conferencesessions, posters and exhibits, foodfunctions, and access to the conferenceproceedings link.Handicapped Equal Access: In accordancewith the ADA, Cambridge HealthtechInstitute is pleased to arrange specialaccommodations for attendees withspecial needs. All requests for suchassistance must be submitted in writingto CHI at least 30 days prior to the startof the meeting.To view our Substitutions/Cancellations Policy, go tohttp://www.healthtech.com/regdetailsVideo and or audio recording of any kindis prohibited onsite at all CHI events.Receive a FREE eNewsletter by signing upat chimediagroup.comThe latest industry news, commentaryand highlights from Bio-IT WorldInnovative management in clinical trialsA series of diverse reports designed tokeep life science professionals informedof the salient trends in pharmaceuticaltechnology, business, clinical development,and therapeutic disease markets.For a detailed list of reports, visitInsightPharmaReports.com, or contactRose LaRaia, email@example.com,+1-781-972-5444.Barnett is a recognized leader in clinicaleducation, training, and reference guidesfor life science professionals involved inthe drug development process. For moreinformation, visit barnettinternational.com.Cambridge Healthtech Associates™(CHA™) leverages its extensive networkand unique collaborative model inconsulting, technology evaluationsand community-based communicationservices to help clients in the lifesciences industry commercialize andpenetrate the marketplace to increaserevenue. Visit www.chacorporate.com.Cambridge Healthtech Institute, 250 First Avenue, Suite 300, Needham, MA 02494 • www.healthtech.com • Fax: 781-972-5425Pricing and Registration Informationshort courses Academic, Government,(Includes access to short courses only) Commercial Hospital-affiliatedSingle Short Course $699 $399Two Short Courses $999 $6993 Day Pricing • August 13-15(Excludes short courses)Package A - Novel Vaccines: Innovations & AdjuvantsEarly Registration Deadline until May 17, 2013 $2049 $1025Advance Registration Deadline until July 19, 2013 $2199 $1099Registrations after July 19, 2013 and on-site $2399 $1149Package B - Emerging Cancer Immunotherapies and Vaccines + Immunomodulatory Antibodies for CancerEarly Registration Deadline until May 17, 2013 $2049 $1025Advance Registration Deadline until July 19, 2013 $2199 $1099Registrations after July 19, 2013 and on-site $2399 $11491.5 Day Pricing(Excludes short courses)Package A - Emerging Cancer Immunotherapies and Vaccines • August 13-14Early Registration Deadline until May 17, 2013 $1399 $649Advance Registration Deadline until July 19, 2013 $1599 $729Registrations after July 19, 2013 and on-site $1799 $799Package B - Immunomodulatory Antibodies for Cancer • August 14-15Early Registration Deadline until May 17, 2013 $1399 $649Advance Registration Deadline until July 19, 2013 $1599 $729Registrations after July 19, 2013 and on-site $1799 $799Conference DiscountsPoster Submission-Discount ($50 Off)Poster abstracts are due by July 19, 2013. Once your registration has been fully processed, we will send an email containing a unique linkallowing you to submit your poster abstract. If you do not receive your link within 5 business days, please contact firstname.lastname@example.org.*CHI reserves the right to publish your poster title and abstract in various marketing materials and products.Alumni Discount-Discount (SAVE 20%)Cambridge Healthtech Institute (CHI) appreciates your past participation at the ImVacS & the Immunotherapies Congress. As a result of thegreat loyalty you have shown us, we are pleased to extend to you the exclusive opportunity to save an additional 20% off the registrationrate.REGISTER 3 - 4th IS FREE: Individuals must register for the same conference or conference combination and submit completed registration form togetherfor discount to apply.Additional discounts are available for multiple attendees from the same organization. For more information on group rates contactDavid Cunningham at +1-781-972-5472If you are unable to attend but would like to purchase the ImVacS & the Immunotherapies Congress CD for $750 (plus shipping),please visit ImVacS.com. Massachusetts delivery will include sales tax.How to Register: ImmunotherapiesCongress.email@example.com • P: 781.972.5400 or Toll-free in the U.S. 888.999.6288Please use keycodeIMT Pwhen registering!(Alumni and Register 3 - 4th is free discounts cannot be combined)ImmunoTheCongressherapiesAugust 13-15, 2013Boston, MA